Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 17/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16321603 | 0.81 | NPC1 (0.44) | IDO1LMNANPC1PKMNFKB1 | |
| SCHEMBL14693884 | 0.80 | IDO1 (0.53) | IDO1LMNANPC1PKMNFKB1 | |
| SCHEMBL14237485 | 0.80 | IDO1 (0.48) | IDO1LMNANPC1PKMNFKB1 | |
| SCHEMBL4055463 | 0.80 | IDO1 (0.39) | IDO1LMNANPC1PKMNFKB1 | |
| SCHEMBL12230586 | 0.78 | PRKCI (0.53) | PRKCIIDO1LMNA | |
| SCHEMBL4050159 | 0.77 | NPC1 (0.39) | IDO1LMNANPC1PKMNFKB1 | |
| SCHEMBL16340838 | 0.77 | IDO1 (0.40) | IDO1LMNANPC1PKMNFKB1 | |
| SCHEMBL16341406 | 0.77 | IDO1 (0.50) | IDO1LMNANPC1PKMNFKB1 | |
| SCHEMBL6046592 | 0.77 | IDO1 (0.36) | IDO1LMNANPC1PKMNFKB1 | |
| SCHEMBL16320974 | 0.77 | IDO1 (0.36) | IDO1LMNANPC1PKMNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140377292-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2014-12-25 | — | — | US | claimed |
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION | 2006-11-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | IDO1, IDO2, INMT | PRKCI 3118/4885IDO1 1/4885LMNA 4866/4885 |
| US-20140377292-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | PRKCI 3118/4885IDO1 1/4885LMNA 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.